Age, Biography and Wiki
Nicholas P. Restifo was born on 24 July, 1960 in Columbus, Ohio, is an American physician. Discover Nicholas P. Restifo's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 63 years old?
| Popular As |
N/A |
| Occupation |
Immunologist |
| Age |
63 years old |
| Zodiac Sign |
Leo |
| Born |
24 July 1960 |
| Birthday |
24 July |
| Birthplace |
Columbus, Ohio |
| Nationality |
United States
|
We recommend you to check the complete list of Famous People born on 24 July.
He is a member of famous physician with the age 63 years old group.
Nicholas P. Restifo Height, Weight & Measurements
At 63 years old, Nicholas P. Restifo height not available right now. We will update Nicholas P. Restifo's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Nicholas P. Restifo Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Nicholas P. Restifo worth at the age of 63 years old? Nicholas P. Restifo’s income source is mostly from being a successful physician. He is from United States. We have estimated Nicholas P. Restifo's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
physician |
Nicholas P. Restifo Social Network
Timeline
Nicholas P. Restifo (born July 24, 1960) is an American immunologist, physician and educator in cancer immunotherapy.
Restifo was born July 24, 1960, in Columbus, Ohio.
He grew up in a small town, Amherst, Ohio, and went to high school in Lorain, Ohio.
He completed his undergraduate education with honors at the Johns Hopkins University and obtained his medical degree from New York University School of Medicine.
He first joined the National Cancer Institute, NIH in Bethesda, Maryland in 1989.
He was recruited from the Memorial Sloan Kettering Cancer Center, where he worked in the laboratory of Murray Brennan, the former chairman of Surgery.
He became a principal investigator in 1993 and has authored or co-authored more than 350 papers and book chapters on cancer immunotherapy.
His h-index is 156 and his work has been cited more than 104,000 times according to Google Scholar.
Restifo is a pioneer in the field of cancer immunotherapy with a focus on the use of T cells in the treatment of malignancy.
One of Dr. Restifo's major discoveries is that CD8+ T cells experience a stereotypical maturational program.
His early work was focused on discovering how tumor cells can escape from T cell recognition.
He went on to characterize the mechanisms underlying why T cells survive and expand better after lymphodepletion.
His most recent efforts include a focus on how elements – literally from the periodic table – influence cancer immunity.
These include work on how oxygen can inhibit anti-tumor immunity and how potassium ions from dying cancer cells can shut down the anti-tumor response.
Successful treatment of patients with cancer is the goal of his laboratory, and his therapeutic approaches employ adoptive T cell transfer, gene modification and cellular reprogramming.
Basic aspects of tumor and T cell immunology inform novel therapeutic interventions in the clinic.
Restifo and his research team have made contributions to the fields of adoptive cell transfer tumor immune-escape, virally encoded cancer vaccines, adoptive cell transfer for the treatment of cancer, and the biology of self/tumor-reactive T cells, with an emphasis on memory CD8+ T cells.
Clarivate Analytics, “World’s Most Influential Scientific Minds” Double Citation in Immunology and Clinical Medicine 2014 (Thomson Reuters)
Academic Appointments, primary mentor for PhD students: 2014 Cambridge University, UK; 2011 U of Pennsylvania School of Medicine; 2010 Georgetown U School of Medicine; 2009 George Wash U School of Medicine.
Solomon A. Berson Prize for Clinical and Translational Science, 2017
NIH Director’s Award, 2017, Federal Technology Transfer Award, 2017
Primary Organizer of four Keystone Symposia and three International Cancer Immunotherapy Meetings at NIH.
Plenary and Keynote Invited talks at AACR, SITC, ASH, ASCGT, AAI and other meetings.
Until July 2019, he was a tenured senior investigator in the intramural National Cancer Institute of the National Institutes of Health at Bethesda, Maryland.
Nicholas was an executive vice president of research at Lyell based in San Francisco.
Restifo has been a pioneer in the use of T cell-based immunotherapy.
